CorMedix completes acquisition of Melinta Therapeutics, expanding and diversifying its commercial product portfolio.
Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026.
Revised guidance estimates pro forma 2025 combined revenues to be in the range of $325 to $350 million.
Transformational Deal with Melinta
Expands and diversifies CorMedix's commercial product portfolio with seven innovative drug products and pipeline expansion indication.
Financial Impact
Revised guidance indicates near-term accretion to EPS with annual run-rate synergies expected to be between $35 to $45 million.
Revenue Growth Potential
Revised pro forma 2025 revenue guidance ranges from $325 to $350 million, highlighting significant growth opportunities.
Key Leadership Changes
Senior leadership team announcements with executives from both CorMedix and Melinta assuming key roles in the merged company.
- The acquisition strengthens CorMedix's portfolio with seven marketed products, enhancing revenue and reach in infectious disease.
- Melinta's portfolio provides a revenue base and cash flow boost, with expectations of delivering $125 to $135 million in revenue for FY 2025.
- The combined entity anticipates synergies of $35 to $45 million in both the near-term and with potential future expansion strategies.
The acquisition of Melinta Therapeutics marks a significant milestone for CorMedix, positioning the company for substantial growth and diversification in the biopharmaceutical sector.